Estimating costs for treating patients with multi-drug resistant tuberculosis (MDR TB) under the regional tuberculosis control program, Tomsk (Russia) Source: International Congress 2015 – Treatment of TB (MDR-TB): co-morbidities, adverse effects and outcomes Year: 2015
Safety and efficacy of exposure to bedaquiline-delamanid in multidrug-resistant tuberculosis: a case series from France and Latvia Source: Eur Respir J, 51 (3) 1702550; 10.1183/13993003.02550-2017 Year: 2018
Outcomes of MDR cases in Iasi county, Romania Source: Annual Congress 2005 - Resistant and multidrug resistant tuberculosis Year: 2005
Multidrug-resistant and extensively drug resistance tuberculosis has a strong public health and economical impact in the Republic of Moldova Source: Annual Congress 2013 –Tuberculosis and latent tuberculosis infection in subpopulations Year: 2013
Prevalence of aminoglycoside resistance among different MDR tuberculosis cases in Ukraine Source: Annual Congress 2013 –Drug-resistant tuberculosis Year: 2013
Treatment outcome of multi-drug resistant tuberculosis in the Republic of Moldova Source: International Congress 2017 – TB: co-morbidities and outcome Year: 2017
Drug resistant tuberculosis in Odessa, Southern Ukraine: Beijing family strains prevalence and the role of prisons in drug resistant TB transmission Source: Eur Respir J 2006; 28: Suppl. 50, 290s Year: 2006
Dynamics analysis of MBT drug resistance to antitubercolosis second-line drugs (Saratov region hospital, Russia) Source: International Congress 2016 – Update on drug-resistant tuberculosis Year: 2016
Prevalence of fluoroquinolon-resistance among different MDR tuberculosis cases in Ukraine Source: Annual Congress 2013 –Drug-resistant tuberculosis Year: 2013
Alarming levels of drug-resistant tuberculosis in Belarus: results of a survey in Minsk Source: Eur Respir J 2012; 39: 1425-1431 Year: 2012
Molecular surveillance of multi-drug resistant tuberculosis in Europe Source: Annual Congress 2007 - Multidrug-resistant tuberculosis and the emerging threat of extensively drug-resistant tuberculosis Year: 2007
Rifampicin-resistant tuberculosis (RR-TB) in eastern Europe Source: International Congress 2016 – Rifampicin resistance, MDRTB, and new drug treatments Year: 2016
Active pharmacovigilance for multidrug-resistant tuberculosis patients treated with Linezolid, Belarus – 2014-2015 Source: International Congress 2015 – Treatment of TB (MDR-TB): co-morbidities, adverse effects and outcomes Year: 2015
Multidrug-resistance tuberculosis and HIV-infected patients, the effectiveness of the treatment in Ukraine Source: Annual Congress 2010 - Tuberculosis drug resistance Year: 2010
Facilities for treating multidrug-resistant tuberculosis (MDRTB) in Europe Source: International Congress 2016 – New insights into aspects of tuberculosis epidemiology Year: 2016
Current status of fluoroquinolone use for treatment of tuberculosis in Korea Source: Annual Congress 2013 –Drug-resistant tuberculosis Year: 2013
Determinants of multidrug-resistant tuberculosis (MDR-TB) in Belarus Source: Annual Congress 2012 - MDR- and XDR-TB: epidemiological and public health overview Year: 2012
Effectiveness of the WHO regimen for treatment of multidrug resistant tuberculosis (MDR-TB) Source: Annual Congress 2013 –Drug-resistant tuberculosis: new clinical and public health insights Year: 2013
Trend in TB control in Republic of Moldova: High MDRTB burden country Source: International Congress 2014 – Tuberculosis: epidemiology and public health Year: 2014
Concurrent use of bedaquiline and delamanid for the treatment of fluoroquinolone-resistant multidrug-resistant tuberculosis: a nationwide cohort study in South Korea Source: Eur Respir J, 57 (3) 2003026; 10.1183/13993003.03026-2020 Year: 2021